stockrow
Friday 6 November 2026
Export TEVA’s income statement to Excel — free account
Teva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
42.25
0.47
+1.12%
Follow TEVA
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
87.86 | 53.78 | 21.99 | 25.17 |
+8 more quarters Free account |
P/S ratio |
2.68 | 2.28 | 2.01 | 2.07 | |
P/FCF ratio |
34.77 | 28.17 | 28.28 | 30.23 | |
P/Operating CF |
191.59 | 96.03 | (870.47) | 30.86 | |
P/B ratio |
5.78 | 5.09 | 4.23 | 4.52 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.41 | 3.03 | 2.75 | 2.84 | |
EV/EBITDA |
25.18 | 20.91 | 14.52 | 15.50 | |
EV/Operating CF |
33.22 | 27.61 | 27.83 | 29.71 | |
EV/FCF |
44.28 | 37.41 | 38.75 | 41.44 | |
Quick Ratio |
0.51 | 0.46 | 0.53 | 0.54 | |
Current Ratio |
0.95 | 0.88 | 1.01 | 1.04 | |
Net Debt/EBITDA |
13.17 | 82.40 | 14.46 | 40.40 | |
Debt/Assets |
41.75% | 41.63% | 41.53% | 41.24% | |
Debt/Equity |
2.09 | 2.14 | 2.02 | 2.12 | |
Asset Turnover |
0.43 | 0.43 | 0.44 | 0.43 | |
Operating CF/Net income |
1.03 | (0.71) | (0.11) | 2.41 | |
Capex/Depreciation |
(0.30) | (0.42) | (0.53) | (0.55) | |
Research and Development Expense of Revenue |
6.76% | 23.42% | 5.58% | 5.65% | |
Selling, General and Administrative Expense of Revenue |
22.91% | 24.96% | 25.11% | 23.82% | |
Intangible Assets out of Total Assets |
0.48 | 0.48 | 0.49 | 0.49 | |
Share Based Compensation of Revenue |
0.86% | 0.97% | 1.08% | 1.08% | |
Graham Net Nets |
(0.38) | (0.46) | (0.52) | (0.53) | |
Graham Number |
8.33 | 9.72 | 14.82 | 13.89 | |
Earnings Yield |
1.14% | 1.86% | 4.55% | 3.97% | |
Free Cash Flow Yield |
2.88% | 3.55% | 3.54% | 3.31% | |
Revenue per Share |
3.77 | 3.56 | 3.44 | 4.11 | |
Operating CF per Share |
0.21 | 0.35 | (0.03) | 1.01 | |
Capex per Share |
(0.06) | (0.09) | (0.11) | (0.12) | |
Free Cash Flow per Share |
0.14 | 0.27 | (0.14) | 0.89 | |
Cash per Share |
3.50 | 3.14 | 3.24 | 3.11 | |
Shareholders Equity per Share |
6.85 | 6.66 | 7.12 | 6.91 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.85 | 6.66 | 7.12 | 6.91 | |
Free Cash Flow |
168.00 | 310.00 | (166.00) | 1,016.00 | |
Working Capital |
(823.00) | (1,886.00) | 178.00 | 490.00 | |
Capital Expenditures |
(73.00) | (101.00) | (126.00) | (142.00) | |
Net Current Asset Value |
(17,455.00) | (18,340.00) | (18,099.00) | (18,888.00) | |
EV/EBIT |
43.56 | 34.52 | 20.84 | 22.70 | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.03 | |
Price to Operating Income |
34.20 | 26.00 | 15.21 | 16.56 | |
| Other line items | |||||
Average Receivables |
3,823.50 | 3,528.50 | 3,388.50 | 3,384.00 | |
Average Payables |
2,453.00 | 2,609.50 | 2,443.00 | 2,367.00 | |
Average Inventory |
3,248.00 | 3,359.00 | 3,211.50 | 3,093.00 | |
Average Assets |
39,949.00 | 39,994.00 | 39,227.50 | 40,037.00 | |
Average Common Equity |
7,619.00 | 7,295.00 | 7,250.50 | 6,647.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026